Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Capital Employed (2018 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Return on Capital Employed readings, the most recent being 6.01% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 921.0% to 6.01% in Q1 2026 year-over-year; TTM through Mar 2026 was 6.01%, a 921.0% increase, with the full-year FY2025 number at 4.19%, up 1426.0% from a year prior.
  • Return on Capital Employed hit 6.01% in Q1 2026 for Kiniksa Pharmaceuticals International, up from 3.73% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 9.16% in Q2 2023 to a low of 71.98% in Q1 2022.
  • Median Return on Capital Employed over the past 5 years was 4.47% (2023), compared with a mean of 9.0%.
  • Biggest five-year swings in Return on Capital Employed: soared 8147bps in 2022 and later crashed -1531bps in 2024.
  • Kiniksa Pharmaceuticals International's Return on Capital Employed stood at 2.37% in 2022, then crashed by -341bps to 5.71% in 2023, then crashed by -71bps to 9.76% in 2024, then soared by 138bps to 3.73% in 2025, then skyrocketed by 61bps to 6.01% in 2026.
  • The last three reported values for Return on Capital Employed were 6.01% (Q1 2026), 3.73% (Q4 2025), and 6.78% (Q3 2025) per Business Quant data.